New hope for brain tumor patients: targeted drug combo shows promise
NCT ID NCT07215910
First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 28 times
Summary
This study tests whether adding a targeted drug called vorasidenib to standard treatment (radiation and chemotherapy) can help people with a specific type of brain tumor (grade 3 astrocytoma with IDH mutation). About 408 participants will receive either vorasidenib or a placebo alongside usual care. The goal is to see if the new combination delays tumor growth better than standard treatment alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTROCYTOMA, IDH-MUTANT, GRADE 3 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.